SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction
SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction
SciSparc獲得FDA批准，在美國啓動關鍵性IIb期試驗，用於治療[link:特瑞特綜合症]（Tourette Syndrome）的SCI-110，此前IIa期結果令人振奮，顯示最多可減少40%的抽動。
SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction
SciSparc獲得FDA批准，在美國啓動關鍵性IIb期試驗，用於治療[link:特瑞特綜合症]（Tourette Syndrome）的SCI-110，此前IIa期結果令人振奮，顯示最多可減少40%的抽動。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。